AXSM (axsome.com) Company Future Sales Volume
Axsome Therapeutics (AXSM) is expanding its influence in neuroscience through platform acquisitions and clinical partnerships. The company's sales volume forecast confirms this potential, with the value of 0.87 serving as the baseline metric. The business is shielded from economic crises due to the specific nature of CNS drugs, while a robust patent shield precludes price wars and dumping, thereby minimizing market risks.
Financial and market metric breakdowns for Axsome (AXSM)
- current price and projected stock value:
- business market valuation indicators:
- issuer book value statistics:
- debt and solvency information:
Debt to Equity Axsome Therapeutics|AXSM - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Axsome Therapeutics Inc|AXSM - Company Aggregate Debts|Debt to Book Capitalization Ratio Axsome|AXSM - Long-Term Liabilities|Company Short-Term Debts Axsome Therapeutics|Quick Liquidity Indicator axsome.com
- earnings and market ratios statistics:
AXSM - Net Profit|Future Profit Axsome Therapeutics|AXSM - Market Price to Net Income Ratio|Forward P/E Multiple Axsome Therapeutics, Inc.|AXSM - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Axsome|AXSM - Operating profit before deduction of amortization|Earnings per share for the last twelve months Axsome Therapeutics|AXSM - Net earnings per share for the last four quarters|Quarterly EPS earnings growth axsome.com|AXSM - Earnings growth in current year|Expected earnings per share growth for next year Axsome Therapeutics
- sales volume and revenue information:
Comprehensive company analysis:AXSM Axsome Therapeutics
The implementation of AI algorithms into the clinical trial analysis of Axsome Therapeutics (AXSM) accelerates the time-to-market for neuropsychiatric drugs, directly impacting future revenue dynamics. By analyzing the organization's prospective sales volume, the investor assesses market revenue expectations, where a breach of critical levels signals rising credit risks and necessitates a reduction in leverage to ensure capital stability.
Competitor analysis for Axsome Therapeutics
Company Future Sales Volume BIIB (Biogen Inc.)|NBIX (neurocrine.com) - Company Future Revenue|Regencell Bioscience Holdings Limited - Company Future Sales Volume|Company Projected Revenue Volume ACAD (ACADIA Pharma)|Xenon Pharmaceuticals Inc - Projected Sales Volume|Company Future Revenue VKTX (Viking Therapeutics Corp)|SUPN: Projected Sales Volume|Company Expected Sales Volume catalystpharma.com (CPRX)|Company Projected Revenue Denali Therapeutics Inc.|HRMY: Company Future Revenue|Projected Sales Volume BHVN|Projected Sales Volume Amylyx Corp (AMLX)|Company Projected Revenue Trevi Therapeutics TRVI|PRAX (praxismedicines.com) - Company Expected Revenue|Anavex Life Sciences Corp. - Projected Sales Volume|Company Expected Sales Volume CeriBell Inc|PRTA (Prothena Corporation PLC) - Company Future Sales Volume|Alector (ALEC) - Projected Sales Volume|Company Future Sales Volume ANNX|OMER (Omeros Corp.) - Company Projected Revenue Volume|Projected Sales Volume NGNE|Company Future Sales AC Immune S.A.|Projected Sales Volume VYGR (Voyager Pharma)|NMRA - Company Future Sales Volume|SCLX - Company Projected Revenue|Company Future Sales tevogen.com TVGN|ACOG: Projected Sales Volume|cogrx.com (CGTX) - Projected Sales Volume|Company Future Sales Volume IKT|Company Revenue Forecast SAVA (Cassava Pharma)|Company Projected Revenue Assertio Holdings, Inc. (ASRT)|Company Future Sales coyatherapeutics.com|Company Projected Revenue Vistagen VTGN|OVID - Company Future Sales Volume|ABOS - Company Projected Revenue|CRVO (CervoMed Corporation) - Company Revenue Forecast|ATHE: Projected Sales Volume|Company Expected Sales Volume Clene (CLNN)|Company Future Sales Volume PEPG|Projected Sales Volume jupiterneurosciences.com|Company Projected Revenue Relmada (RLMD)|ANVS (Annovis Bio Corporation) - Company Future Revenue|Company Projected Revenue Grace Therapeutics GRCE|fireflyneuro.com (AIFF) - Company Expected Sales Volume|ANEW Medical, Inc. - Projected Sales Volume|NRSN - Projected Sales Volume|RVPH (Reviva Pharmaceuticals Holdings) - Company Future Sales Volume|Company Revenue Forecast MTVA|Company Projected Revenue NeurAxis, Inc.|Helius Medical Technologies Inc. (HSDT) - Company Future Sales|Company Projected Revenue Passage Bio, Inc. (PASG)|NEUP - Company Expected Sales Volume|Company Projected Revenue Minerva Neurosciences Corp NERV|ATHA - Company Future Sales Volume|Addex Therapeutics - Projected Sales Volume|Company Expected Sales Volume Alzamend Neuro, Inc.|CYCN (cyclerion.com) - Company Future Sales Volume|Protagenic Therapeutics, Inc. - Company Future Revenue|Company Future Sales Volume KTTA|CRGT (Cortigent Medical) - Company Projected Revenue Volume|Projected Sales Volume ATXI|BCLI (brainstorm-cell.com) - Company Future Revenue|Projected Sales Volume CARA (Cara Therapeutics)|Chromocell Therapeutics Corp (CHRO) - Company Expected Sales Volume|ELYM - Company Projected Revenue|Company Future Revenue ITCI (Intra-Cellular Therapies)|LBPH: Projected Sales Volume|marinuspharma.com (MRNS) - Projected Sales Volume|Company Projected Revenue NKGen Biotech|NeuroBo Pharmaceuticals Inc - Company Expected Revenue|Projected Sales Volume SAGE|SNPX - Company Expected Sales Volume|Trevena, Inc. - Company Future Sales Volume|Projected Sales Volume Vigil Neuroscience Inc. VIGL|WENA: Company Future Sales Volume|Cerevel Therapeutics Inc - Company Projected Revenue Volume
